FDA Approved: IDHIFA — Supplemental Application (Celgene Corporation)

View source ↗

Summary

FDA approved a supplemental application for IDHIFA (enasidenib mesylate) to expand its labeling for acute myeloid leukemia with IDH2 mutation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• IDHIFA (enasidenib)

Snippet

SUPPL AP for IDHIFA (ENASIDENIB MESYLATE)